Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor

19 Aug 2013

Abstract excerpt

Cancer development and chemo-resistance are often due to impaired functioning of the p53 tumor suppressor through genetic mutation or sequestration by other proteins. In glioblastoma multiforme (GBM), p53 availability is frequently reduced because it binds to the Murine Double Minute-2 (MDM2) oncoprotein, which accumulates at high concentrations in tumor cells. The use of MDM2 inhibitors that interfere with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Glioma Diagnosis and Treatment
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23977270
DOI: 10.1371/journal.pone.0072281

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 InhibitorPMID 23977270Read ↗

MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted TherapySemantic proximity Read ↗

HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.Semantic proximity Read ↗

Biology of Glioblastoma Multiforme—Exploration of Mitotic Catastrophe as a Potential Treatment ModalitySemantic proximity Read ↗

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trialsSemantic proximity Read ↗

Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of ActionSemantic proximity Read ↗

MDM2: current research status and prospects of tumor treatmentSemantic proximity Read ↗

MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell LinesSemantic proximity Read ↗

Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells.Semantic proximity Read ↗

Preclinical Efficacy of the MDM2 Inhibitor RG7112 in <i>MDM2</i> -Amplified and <i>TP53</i> Wild-type GlioblastomasSemantic proximity Read ↗

MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)Semantic proximity Read ↗

Modified Adenosines Sensitize Glioblastoma Cells to Temozolomide by Affecting DNA MethyltransferasesSemantic proximity Read ↗

Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.